Related Experiment Video

Updated: Sep 28, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations

Oscar Villacañas1, Juan J Pérez, Jaime Rubio-Martínez

  • 1Department de Química Física, Universitat de Barcelona, Martí i Franquès, 1, Spain.

Journal of Biomolecular Structure & Dynamics
|November 20, 2002
PubMed

Insights

Molecular dynamics simulations reveal key interactions between cyclin-dependent kinases 4/6 (Cdk4/6) and the p16INK4a tumor suppressor. This research aids in developing cancer treatments by understanding how p16INK4a inhibits cell division.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Cyclin-dependent kinases 4, 6, and 2 (Cdk4/6/2) regulate cell cycle progression through the G1-S transition.
  • The p16INK4a tumor suppressor inhibits Cdk4/6, arresting cell division and preventing cancer progression.
  • Inhibition of p16INK4a is common in many cancers, making its interaction with Cdks a therapeutic target.

Purpose of the Study:

  • To investigate the molecular interactions between Cdk4/6 and the p16INK4a tumor suppressor.
  • To gain insights into the mechanisms of Cdk inhibition by p16INK4a for potential cancer therapy development.

Main Methods:

  • Molecular dynamics simulations of Cdk6-p16INK4a and Cdk4-p16INK4a complexes at 300 K.
  • Analysis of key interactions, T-loop conformation, and ATP binding-site distortion.

Main Results:

  • Simulations confirmed previously identified key interactions between Cdk6 and p16INK4a.
  • New insights were gained into the role of the T-loop conformation in Cdk inhibition.
  • The study elucidated how p16INK4a binding distorts the ATP binding-site of Cdks.

Conclusions:

  • Molecular dynamics simulations provide a deeper understanding of Cdk-p16INK4a interactions.
  • Findings can inform the design of novel small-molecule inhibitors targeting Cdk4/6 for cancer treatment.
  • Understanding these interactions is crucial for developing effective cancer therapies.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis08:33

Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis

Published on: December 5, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...